NCT06175065View on ClinicalTrials.gov

Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 25, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Interventions
DRUG

RLS-0071

RLS-0071, will be administered as an IV infusion 10 mg/kg. Planned infusion duration is 8 minutes.

DRUG

Placebo

Placebo control (commercial sterile saline), will be administered as an IV infusion. Planned infusion duration is 8 minutes.

Trial Locations (4)

19122

Site 01, Philadelphia

21061

Site 03, Glen Burnie

33701

Site 02, St. Petersburg

68198

Site 04, Omaha

All Listed Sponsors
lead

ReAlta Life Sciences, Inc.

INDUSTRY

NCT06175065 - Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter